Evidence map›Paper›PMID 41034006›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil.

Mitsuki Otsuka, Shiro Sonoda, Takayuki Yamada, Shotaro Aoki, Tomoka Yasuda, Atsushi Sawada, Tsuyoshi Shirai, Tomoya Tateishi, Haruhiko Furusawa, Yasunari Miyazaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mitsuki OtsukaDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Shiro SonodaDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Takayuki YamadaDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Shotaro AokiDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Tomoka YasudaDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Atsushi SawadaDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Tsuyoshi ShiraiDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Tomoya TateishiDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Haruhiko FurusawaDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.
Yasunari MiyazakiDepartment of Respiratory Medicine, Institute of Science Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhaled treprostinil is the first-choice drug for the treatment of Group 3 pulmonary hypertension (PH) associated with chronic lung disease. A 72-year-old man was diagnosed with interstitial pneumonia, and his respiratory symptoms had gradually worsened. Echocardiography revealed a maximum tricuspid regurgitation pressure gradient (TRPG) of 64 mmHg, and the patient was diagnosed with Group 3 PH. Subsequently, he was admitted to the hospital with acute heart failure. Inhaled treprostinil was prescribed, his B-type natriuretic peptide level and maximum TRPG subsequently improved, and his oxygen requirement decreased. Treprostinil inhalation may be effective in treating patients with severe respiratory symptoms of interstitial pneumonia.

Indexed as

Antihypertensive AgentsEpoprostenolHypertension, PulmonaryLung Diseases, InterstitialAdministration, InhalationAgedHumansMaleSeverity of Illness IndexTreatment OutcomeAntihypertensive AgentsEpoprostenoltreprostinilBNPchronic lung diseaseGroup 3 pulmonary hypertensionTRPG

Identifiers

PMID41034006
PMCPMC13294586

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.